Journal of Shandong University (Health Sciences) ›› 2021, Vol. 59 ›› Issue (9): 1-8.doi: 10.6040/j.issn.1671-7554.0.2021.0949

    Next Articles

New practice of radio-immunotherapy for lung cancer

YU Jinming, YAN Weiwei, CHEN Dawei   

  1. Shandong Cancer Hospital Affiliated to Shandong University, Jinan 250117, Shandong, China
  • Published:2021-10-15

RichHTML

25

PDF (PC)

331

Abstract: In recent years, immunotherapy combined with radiotherapy(iRT)has attracted great attention in the field of oncology, and hundreds of large clinical trials on iRT are currently underway. Radiotherapy can cause immunogenic death of tumor cells, promote the release and presentation of tumor antigens, and activate T cells. Radiotherapy can also reshape the tumor microenvironment from immunosuppression to immune activation. Immune checkpoint inhibitors can not only relieve T cell inhibition but also normalize tumor vessels so as to improve tumor hypoxia and increase radiosensitivity, which is the basic principle of synergistic anti-tumor effect of radiotherapy and immunity. Now iRT is becoming more and more mature, but it also faces many challenges. This paper will review the development of immunotherapy and radiotherapy in recent years, and explore the timing, fractional dose and treatment-related toxicity of iRT.

Key words: Lung cancer, Radiotherapy, Immunotherapy, Immune checkpoint inhibitors

CLC Number: 

  • R734.2
[1] Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting [J]. Nature, 2012, 482(7385): 400-404.
[2] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation [J]. Cell, 2011, 144(5): 646-674.
[3] Roentgen WC. On a new kind of ray(first report)[J]. Munch Med Wochenschr, 1959, 101: 1237-1239.
[4] Thariat J, Hannoun-Levi JM, Sun Myint A, et al. Past, present, and future of radiotherapy for the benefit of patients [J]. Nat Rev Clin Oncol, 2013, 10(1): 52-60.
[5] Ross GM. Induction of cell death by radiotherapy [J]. Endocr Relat Cancer, 1999, 6(1): 41-44.
[6] Mole RH. Whole body irradiation; radiobiology or medicine?[J]. Br J Radiol, 1953, 26(305): 234-241.
[7] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[8] 郑荣寿, 孙可欣, 张思维,等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28. ZHENG Rongshou, SUN Kexin, ZHANG Siwei, et al. Report of cancer epidemiology in China, 2015 [J]. Chinese Journal of Oncology, 2019, 41(1): 19-28.
[9] Weiner LM. Cancer immunotherapy—the endgame begins [J]. N Engl J Med, 2008, 358(25): 2664-2665.
[10] Jacob Bickels, Yehuda Kollender, Ofer Merinsky, et al. Coleys toxin: historical perspective [J]. Isr Med Assoc J, 2002, 4(6): 471-472.
[11] Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy [J]. Science, 2013, 342(6165): 1432-1433.
[12] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade [J]. Science, 2018, 359(6382): 1350-1355.
[13] Guo ZS. The 2018 Nobel Prize in medicine goes to cancer immunotherapy(editorial for BMC cancer)[J]. BMC Cancer, 2018, 18(1): 1086. doi: 10.1186/s12885-018-5020-3.
[14] Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer [J]. N Engl J Med, 2018, 379(21): 2040-2051.
[15] Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer [J]. N Engl J Med, 2018, 378(22): 2078-2092.
[16] Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater [J]. J Clin Oncol, 2019, 37(7): 537-546.
[17] Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [J]. Lancet, 2019, 393(10183): 1819-1830.
[18] Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC [J]. N Engl J Med, 2018, 378(24): 2288-2301.
[19] Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-sell lung cancer [J]. N Engl J Med, 2018, 379(23): 2220-2229.
[20] Goldman JW, Garassino MC, Chen Y, et al. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer(CASPIAN): a randomized, controlled, open-label, phase III study [J]. Lung Cancer, 2020, 149: 46-52. doi: 10.1016/j.lungcan.2020.09.003.
[21] Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study [J]. J Clin Oncol, 2020, 38(1): 1-10.
[22] Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study [J]. J Clin Oncol, 2018, 36(17): 1675-1684.
[23] Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non?small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study [J]. J Clin Oncol, 2019, 37(28): 2518-2527.
[24] Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas [J]. Blood, 2018, 131(1): 68-83.
[25] Tsai KK, Zarzoso I, Daud AI. PD-1 and PD-L1 antibodies for melanoma [J]. Hum Vaccin Immunother, 2014, 10(11): 3111-3116.
[26] Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer [J]. Front Oncol, 2019, 9: 396. doi: 10.3389/fonc.2019.00396.
[27] Smit EF, de Langen AJ. Pembrolizumab for all PD-L1-positive NSCLC [J]. Lancet, 2019, 393(10183): 1776-1778.
[28] Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice [J]. CA Cancer J Clin, 2017, 67(1): 65-85.
[29] Forster MD, Devlin MJ. Immune checkpoint inhibition in head and neck cancer [J]. Front Oncol, 2018, 8: 310. doi: 10.3389/fonc.2018.00310.
[30] Motz GT, Coukos G. Deciphering and reversing tumor immune suppression [J]. Immunity, 2013, 39(1): 61-73.
[31] Scheper W, Kelderman S, Fanchi LF, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers [J]. Nat Med, 2019, 25(1): 89-94.
[32] Jaffray DA. Image-guided radiotherapy: from current concept to future perspectives [J]. Nat Rev Clin Oncol, 2012, 9(12): 688-699.
[33] Kirkpatrick JP, Kelsey CR, Palta M, et al. Stereotactic body radiotherapy: a critical review for nonradiation oncologists[J]. Cancer, 2014, 120(7): 942-954.
[34] Brooks ED, Sun B, Feng L, et al. Association of long-term outcomes and survival with multidisciplinary salvage treatment for local and regional recurrence after stereotactic ablative radiotherapy for early-stage lung cancer [J]. JAMA Netw Open, 2018, 1(4): e181390. doi: 10.1001/jamanetworkopen.
[35] Bernstein MB, Krishnan S, Hodge JW,et al. Immunotherapy and stereotactic ablative radiotherapy(ISABR): a curative approach? [J]. Nat Rev Clin Oncol, 2016, 13(8): 516-524.
[36] Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC [J]. N Engl J Med, 2018, 379(24): 2342-2350.
[37] Stevens R, Macbeth F, Toy E, et al. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer [J]. Cochrane Database Syst Rev, 2015, 1: CD002143. doi: 10.1002/14651858.
[38] Ribatti D, Mangialardi G, Vacca A. Stephen paget and the ‘seed and soil’ theory of metastatic dissemination [J]. Clin Exp Med, 2006, 6(4): 145-149.
[39] Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice [J]. J Clin Invest, 2014, 124(2): 687-695.
[40] Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade [J]. Cancer Res, 2014, 74(19): 5458-5468.
[41] Garon EB, Rizvi NA, Hui RN, et al. Pembrolizumab for the treatment of non-small-cell lung cancer [J]. N Engl J Med, 2015, 372(21): 2018-2028.
[42] Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer [J]. N Engl J Med, 2015, 373(17): 1627-1639.
[43] Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer [J]. N Engl J Med, 2016, 375(19): 1823-1833.
[44] Theelen W, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials [J]. Lancet Respir Med, 2021, 9(5): 467-475.
[45] Theelen W, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial [J]. JAMA Oncol, 2019, 5(9): 1276-1282.
[46] Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study [J]. J Clin Oncol, 2019, 37(28): 2518-2527.
[47] Welsh J, Menon H, Chen D, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial [J]. J Immunother Cancer, 2020, 8(2):e001001. doi: 10.1136/jitc-2020-001001.
[48] Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine [J]. Int J Radiat Oncol Biol Phys, 2012, 84(4): 879-880.
[49] Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment [J]. Blood, 2009, 114(3): 589-595.
[50] 张强, 吴邵雅, 张靖. 放疗对肿瘤微环境的重塑及增强免疫治疗疗效机制的研究进展 [J]. 肿瘤防治研究, 2021, 48(1): 1-6. ZHANG Qiang, WU Shaoya, ZHANG Jing. New insight on tumor microenvironment remodelling and augmented therapeutic efficacy of immunotherapy by radiotherapy [J]. Cancer Research on Prevention and Treatment, 2021, 48(1): 1-6.
[51] Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors [J]. Immunity, 2014, 41(5): 843-852.
[52] Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors [J]. Immunity, 2014, 41(5): 830-842.
[53] Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy [J]. Cancer Cell, 2013, 24(5): 589-602.
[54] Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the game in immunotherapy [J]. Trends Cancer, 2016, 2(6): 286-294.
[55] Dillon MT, Bergerhoff KF, Pedersen M, et al. ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment [J]. Clin Cancer Res, 2019, 25(11): 3392-3403.
[56] Wang Y, Liu ZG, Yuan H, et al. The Reciprocity between radiotherapy and cancer immunotherapy [J]. Clin Cancer Res, 2019, 25(6): 1709-1717.
[57] Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity [J]. Nat Commun, 2017, 8: 15618. doi: 10.1038/ncomms15618.
[58] Buchwald ZS, Wynne J, Nasti TH, et al. Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation [J]. Front Oncol, 2018, 8: 612. doi: 10.3389/fonc.2018.00612.
[59] Chen D, Patel RR, Verma V, et al. Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy [J]. Radiother Oncol, 2020, 150: 114-120. doi: 10.1016/j.radonc.
[60] Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects [J]. Nat Rev Clin Oncol, 2019, 16(2): 123-135.
[61] Huang Y, Snuderl M, Jain RK. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity [J]. Cancer Cell, 2011, 19(1): 1-2.
[62] Shin SC, Lee KM, Kang YM, et al. Alteration of cytokine profiles in mice exposed to chronic low-dose ionizing radiation [J]. Biochem Biophys Res Commun, 2010, 397(4): 644-649.
[63] Ina Y, Sakai K. Activation of immunological network by chronic low-dose-rate irradiation in wild-type mouse strains: analysis of immune cell populations and surface molecules [J]. Int J Radiat Biol, 2005, 81(10): 721-729.
[64] Barsoumian H, Cushman TR, Caetano MDS, et al. Low dose radiation improves anti-tumor responses in a phase 2 prospective trial of concurrent or sequential stereotactic radiation and ipilimumab in patients with metastatic lesions[J]. International Journal of Radiation Oncology Biology Physics, 2018, 102(3): S26-S26.
[65] Arnold KM, Flynn NJ, Raben A, et al. The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules [J]. Cancer Growth Metastasis, 2018, 11:1 179064418761639. doi: 10.1177/1179064418761639.
[66] Yang H, Jin T, Li M,et al. Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges [J]. Precision Clinical Medicine, 2019, 2(1): 57-70.
[67] Bang A, Schoenfeld JD. Immunotherapy and radiotherapy for metastatic cancers [J]. Ann Palliat Med, 2019, 8(3): 312-325.
[68] Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors [J]. J Clin Oncol, 2018, 36(16): 1611-1618.
[69] Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer [J]. N Engl J Med, 2017, 377(20): 1919-1929.
[70] Bang A, Wilhite TJ, Pike LRG, et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy [J]. Int J Radiat Oncol Biol Phys, 2017, 98(2): 344-351.
[71] Durm GA, Jabbour SK, Althouse SK, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179 [J]. Cancer, 2020, 126(19): 4353-4361.
[72] McCusker MG, Scilla KA, Simone CB, et al. Proton beam therapy and immune checkpoint inhibitors in malignant pleural mesothelioma [J]. J Thorac Oncol, 2019, 14(9): e185-e187.
[73] Shibaki R, Akamatsu H, Fujimoto M, et al. Nivolumab induced radiation recall pneumonitis after two years of radiotherapy [J]. Ann Oncol, 2017, 28(6): 1404-1405.
[1] Xiangyan RUAN,Jiaojiao CHENG,Juan DU,Muqing GU. Ovarian tissue cryopreservation and preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 24-30.
[2] HAN Jing, JIA Chunling. Effects of periodontal basic therapy on postoperative pneumonia in patients with lung cancer before thoracic surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 113-118.
[3] GAO Zhongxia, ZHANG Ming, FAN Mingde, TAN Chenyang, WANG Mengdi, WANG Chao, FAN Yuefei, DING Shouluan, WANG Chengwei. Efficacy and prognostic factors of gamma knife in treating 81 cases of brain metastases from lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 44-49.
[4] WANG Fuli, SUN Yinping, QIN Jie, RONG Jiansheng. Efficacy of DC-CIK cells combined with EGFR-TKI for 35 elderly patients with advanced EGFR-mutant lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 110-117.
[5] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[6] CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30-37.
[7] GAO Huijiang, WEI Yucheng. Minimally invasive sleeve lobectomy: opportunities and challenges in the era of immunotherapy [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 23-27.
[8] PENG Yue, LIU Lei, LI Yuan, BIE Fenglong, ZHOU Bolun, LI Runze, JI Ying, BAI Guangyu, TAN Fengwei, GAO Yushun, MU Juwei, XUE Qi, QIU Bin, GAO Shugeng. Comprehensive application of anatomical partial lobectomy and enhanced recovery after surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 44-53.
[9] GAO Shugeng. Application of enhanced recovery after surgery in perioperative management of lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 1-10.
[10] HAN Dingpei, YAN Yue, CAO Yuqin, SUN Xin, HU Yanxia, WANG Minxian, LUO Yan, SHI Yongmei, XIE Qing, HANG Junbiao, LI Hecheng. Expert consensus of Ruijin Hospital on the concept of enhanced recovery after surgery in the clinical practice of thoracic surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 11-16.
[11] LIU Huining, PENG Jun, REN Yingchun, YANG Guang, WANG Wenhao, LIU Jinfeng, TIAN Qing. Comparison of 34 cases of thoracoscopic wedge resection and 21 cases of segmental resection for stage ⅠA1 non-small cell lung cancer in area P [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 38-43.
[12] DING Zichen, WANG Haohua, ZHOU Liwen, CONG Huiwen, LI Chengsheng, BAO Qihan, YANG Yi, WANG Lianyuan, WANG Suzhen, SHI Fuyan. Study on the individualized efficacy for non-small cell lung cancer patients based on Bayesian Additive Regression Tree model [J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 92-98.
[13] DENG Xiaohui, GUO Ling. Applications and progress of immunotherapy in repeated implantation failure [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 32-37.
[14] WANG Zhe, LIU Yujie, MAO Qian, GUAN Peixia, BAO Qihan, LI Chengsheng, QIAO Xiaowei, PAN Qingzhong, WANG Suzhen. Evaluation of the efficacy of different regimens for early triple negative breast cancer based on the inverse probability of treatment weighting method [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 113-118.
[15] PANG Zhaofei, LIU Yong, ZHAO Xiaogang, YAN Tao, CHEN Xiaowei, DU Jiajun. Construction of a stemness-based scoring model predicting the efficacy of immunotherapy in lung adenocarcinoma based on public databases [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 19-28.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(10): 995 .
[2] JIANG Hong-ju,LI Run-zhi, WANG Ying,XU Dong-mei,ZHANG Mei,ZHANG Yun,LI Ji-fu. Relationship between the plasma level of matrix metalloproteinase-9 and structural characteristics of plaques and percutaneous coronary intervention [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(10): 966 -970 .
[3] ZHANG Jie,LI Zhen-hua,SUN Jin-hao,BAO Li-hua,LIU Yue-peng. Protective effects of the invariable magnetic field on oxidative injured Schwann cells[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(3): 229 -232 .
[4] ZHAO Peng,BI Wan-li,LI Ning. Post-processing techniques of spiral CT in adolescent congenital spinal deformity[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(8): 825 -829 .
[5] ZHENG Min,HAO Yue-wei,LIU Xue-ping,ZHAO Ting-ting. Relationship between the HPA-2 and Kozak sequence polymorphism of platelet membrane glycoprotein and cerebral infarction[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(3): 292 -295 .
[6] JIAO Fang-fang,LIU Shi-qing,LI Fei,LI Chang-sheng,WANG Qin,SUN Qing,LU Wei. Therapeutic effects of Huayulifei on expression of SMAD7 and TGF-β in rats with bleomycin-induced pulmonary fibrosis[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(10): 1054 -1058 .
[7] ZHAO Ying， YAN Lei， ZHANG Hui， YU Peng， LI Ming-jiang， ZHAO Xing-bo. Expression of SPAG9 in patients with serous epithelial ovarian tumors[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(2): 98 .
[8] YANG Xi1, GAO Peng2, XUE Yuwen1, WANG Yan2, LIU Wenjun2, ZHANG Xiaofang2
. Expression of DNA methyltransferase 1（DNMT1）in lung adenocarcinoma and its prognosis significance[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(01): 30 -33 .
[9] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(8): 828 -830 .
[10] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(9): 5 -6 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd